- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01525394
A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval
June 20, 2023 updated by: Eisai Inc.
This is a double-blind (vis-a-vis lenvatinib), randomized, placebo-controlled, three-treatment, three-way crossover study in healthy subjects.
There are two phases in this study: Pre-Randomization and Randomization.
The Pre-Randomization Phase consists of Screening and Baseline Period 1.
The Randomization Phase consists of five periods: Treatment Period 1, Baseline Period 2, Treatment Period 2, Baseline Period 3, and Treatment Period 3. Completion of study termination procedures will be performed at Visit 11.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
52
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Washington
-
Tacoma, Washington, United States, 98418
- Charles River
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
Subjects must meet all of the following criteria to be included in this study:
- Normal, healthy male and female subjects greater than or equal to 18 years of age at the time of informed consent.
- All females must have a negative serum human chorionic gonadotropin (hCG) pregnancy test result at Screening and Baseline. Females of child-bearing potential must agree to use a medically acceptable method of contraception (e.g., abstinence, an intrauterine device (IUD), a double-barrier method such as condom + spermicide or condom + diaphragm with spermicide, a contraceptive implant, an oral contraceptive or have a vasectomized partner) throughout the entire study period and for 30 days after study drug discontinuation. The only subjects who will be exempt from this requirement are postmenopausal women (defined as greater than age 50 and at least 12 months of amenorrhea) or subjects who have been sterilized surgically or who are otherwise proven sterile (e.g., bilateral tubal ligation with surgery at least 6 months prior to dosing, hysterectomy, or bilateral oophorectomy with surgery at least 2 months prior to dosing). All women who are of reproductive potential and who are using hormonal contraceptives must have been on a stable dose of the same hormonal contraceptive product for at least 12 weeks prior to dosing and must continue to use the same contraceptive during the study and for 30 days after study drug discontinuation.
- Male patients who are not abstinent or have undergone a successful vasectomy, who are partners of women of childbearing potential must use, or their partners must use a highly affective method of contraception (e.g., condom + spermicide, condom + diaphragm with spermicide, IUD) starting for at least one menstrual cycle prior to starting study drug(s) and throughout the entire study period and for 30 days (longer if appropriate) after the last dose of study drug. Those with partners using hormonal contraceptives must also be using an additional approved method of contraception (as described previously).
- Partners of male and female subjects must use an effective method of contraception (e.g., barrier method, IUD), commencing prior to or at initiation of study drug and continuing for the duration of the study and for 30 days after study drug discontinuation. All females who are of reproductive potential and who are using hormonal contraceptives must have been on a stable dose of the same hormonal contraceptive product for at least 12 weeks prior to dosing and must continue to use the same contraceptive during the study and for 30 days after study drug discontinuation.
- Voluntarily provide written informed consent prior to any study procedures.
- Are willing and able to comply with all aspects of the protocol for the duration of the study.
Exclusion Criteria:
Subjects who meet any of the following criteria will be excluded from participation in the study:
- Subjects with any clinically significant abnormality, including a QTc interval of greater than 450 msec, on 12-lead ECG at the time of the Screening Period, Baseline Periods, or 30 minutes before administration of study drug.
- A history of myocardial infarction, syncope or cardiac arrhythmias.
- A history of uncontrolled hypertension, defined as a systolic pressure of greater than 140 mm Hg and diastolic pressure of greater than 90 mm Hg.
- A history of unstable heart disease or additional risk factors for Torsades de Pointes (TdP) including heart failure, hypokalemia, or a family history of congenital long QT syndrome or unexplained cardiac arrest.
- Subjects with a history of gastrointestinal surgery (hepatectomy, nephrotomy, digestive organ resection, etc.) that may affect PK profiles of lenvatinib.
- Known intolerance to the study drug or moxifloxacin (Avelox) (or any of the excipients).
- A positive result from human immunodeficiency virus (HIV), hepatitis A antibody (HAVAb), hepatitis B surface antigen (HBsAg) or hepatitis C antibody (HCVAb) tests at Screening.
- A known or suspected history of drug or alcohol misuse within 6 months prior to Screening, or who have a positive urine drug test or breath alcohol test at Screening.
- Subjects who participated in another clinical trial of an investigational drug or device within 4 weeks prior to dosing.
- Subjects who received blood products within 4 weeks, or donated blood within 8 weeks, or donated plasma within one week of dosing.
- Subjects who have engaged in heavy exercise within 2 weeks prior to check-in (e.g., marathon runners, weight lifters, etc.).
- Females who are pregnant or breastfeeding.
- Subjects who are unwilling or unable to abide by the requirements of the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebos
|
The Placebo dose will consist of three 4 mg and two 10 mg placebo capsules.
|
Experimental: Lenvatinib Capsules
|
32 mg will be administered orally as three 4 mg and two 10 mg capsules as a single dose.
Other Names:
|
Active Comparator: Moxifloxacin tablets
|
Moxifloxacin 400 mg will be administered orally as one 400 mg tablet.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate the potential for QT/QTc prolongation by 32 mg lenvatinib using a placebo control and moxifloxacin as the positive control.
Time Frame: 2 months
|
2 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate the safety of lenvatinib in healthy subjects.
Time Frame: 2 months
|
2 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Robert Shumaker, Eisai Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2010
Primary Completion (Actual)
August 1, 2011
Study Registration Dates
First Submitted
January 31, 2012
First Submitted That Met QC Criteria
January 31, 2012
First Posted (Estimated)
February 2, 2012
Study Record Updates
Last Update Posted (Actual)
June 22, 2023
Last Update Submitted That Met QC Criteria
June 20, 2023
Last Verified
April 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Anti-Bacterial Agents
- Protein Kinase Inhibitors
- Moxifloxacin
- Lenvatinib
Other Study ID Numbers
- E7080-A001-002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphomas
-
Stanford UniversityNational Institutes of Health (NIH); AmgenCompletedLymphoma, Non-Hodgkin | Lymphomas: Non-Hodgkin | Lymphomas: Non-Hodgkin Peripheral T-Cell | Lymphomas: Non-Hodgkin Cutaneous Lymphoma | Lymphomas: Non-Hodgkin Diffuse Large B-Cell | Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell | Lymphomas: Non-Hodgkin Mantle Cell | Lymphomas: Non-Hodgkin Marginal... and other conditionsUnited States
-
Yale UniversityMerck Sharp & Dohme LLCTerminatedRelapsed Lymphomas | Refractory LymphomasUnited States
-
University of GiessenCompletedMarginal Zone Lymphomas | Non-Hodgkin Lymphomas | Follicular Lymphomas | Immunocytomas | Lymphocytic LymphomasGermany
-
Margrethe Langer BroUniversity of Aarhus; Danish Cancer SocietyCompletedNon Hodgkin´s Lymphomas | Hodgkin´s LymphomasDenmark
-
M.D. Anderson Cancer CenterRecruitingLymphomas | B-cell LymphomasUnited States
-
Abramson Cancer Center of the University of PennsylvaniaCompletedFollicular Lymphomas | CD19+ Diffuse Large B-cell Lymphomas | Mantle Cell LymphomasUnited States
-
Stanford UniversityTerminatedMycosis Fungoides | Lymphomas: Non-Hodgkin | Lymphomas: Non-Hodgkin Peripheral T-Cell | Lymphomas: Non-Hodgkin Cutaneous LymphomaUnited States
-
National Cancer Institute (NCI)CompletedLymphomas | Leukemias | Multiple CancersUnited States
-
Ronald LevyPfizerCompletedLymphoma | Lymphoma, Non-Hodgkin | Lymphomas: Non-Hodgkin | Lymphomas: Non-Hodgkin Follicular / Indolent B-CellUnited States
-
Innovent Biologics (Suzhou) Co. Ltd.CompletedAdvanced Malignant Tumors LymphomasUnited States
Clinical Trials on Lenvatinib
-
Memorial Sloan Kettering Cancer CenterCompletedHead and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Head and Neck Carcinoma | Cutaneous Squamous Cell CarcinomaUnited States
-
Regina Elena Cancer InstituteUniversity of Pisa; University of Roma La Sapienza; University of Turin, Italy; Istituto Oncologico Veneto IRCCS and other collaboratorsRecruitingDifferentiated Thyroid Cancer | GenderItaly
-
Shanghai Junshi Bioscience Co., Ltd.Active, not recruitingAdvanced Hepatocellular Carcinoma (HCC)Italy, Poland, Singapore, United States, China, Ukraine
-
Fudan UniversityActive, not recruitingHepatocellular CarcinomaChina
-
Shandong New Time Pharmaceutical Co., LTDRecruitingHepatocellular CarcinomaChina
-
Cancer Institute and Hospital, Chinese Academy...Active, not recruitingHepatocellular Carcinoma | Radiotherapy | LenvatinibChina
-
CStone PharmaceuticalsActive, not recruitingHepatocellular CarcinomaSpain, China, United States, Poland, Italy, Taiwan
-
Eisai Inc.Merck Sharp & Dohme LLCCompletedSolid TumorsUnited States, China, Belgium, Australia, Italy, Korea, Republic of, Germany, Netherlands, Poland, Romania, Thailand
-
Eisai Inc.CompletedThyroid CancerUnited States, Australia, France, Poland, United Kingdom, Italy
-
Shanghai Zhongshan HospitalActive, not recruitingCholangiocarcinoma, IntrahepaticChina